PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000850364.78915.d9 |
| _version_ | 1827336935476035584 |
|---|---|
| author | J. C. Barrientos P. M. Barr A. R. Mato C. S. Tam P. Ghia C. Moreno N. E. Kay T. Siddiqi E. Szafer-Glusman C. Zhou L. Neumayr G. Krigsfeld W. G. Wierda T. Shanafelt |
| author_facet | J. C. Barrientos P. M. Barr A. R. Mato C. S. Tam P. Ghia C. Moreno N. E. Kay T. Siddiqi E. Szafer-Glusman C. Zhou L. Neumayr G. Krigsfeld W. G. Wierda T. Shanafelt |
| author_sort | J. C. Barrientos |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:42:31Z |
| format | Article |
| id | doaj.art-700c43dce68a48a8aaa01e3669d875fd |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:42:31Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-700c43dce68a48a8aaa01e3669d875fd2024-03-02T03:29:19ZengWileyHemaSphere2572-92412022-06-0161758175910.1097/01.HS9.0000850364.78915.d9202206003-01758PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)J. C. Barrientos0P. M. Barr1A. R. Mato2C. S. Tam3P. Ghia4C. Moreno5N. E. Kay6T. Siddiqi7E. Szafer-Glusman8C. Zhou9L. Neumayr10G. Krigsfeld11W. G. Wierda12T. Shanafelt131 Zucker School of Medicine at Hofstra/Northwell CLL Research & Treatment Program, Lake Success, NY2 Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY3 Memorial Sloan Kettering Cancer Center, New York, NY, United States of America4 Peter MacCallum Cancer Center & St. Vincent’s Hospital and the University of Melbourne, Melbourne, VIC, Australia5 Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy6 Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain7 Mayo Clinic, Rochester, MN8 City of Hope National Medical Center, Duarte, CA9 Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA9 Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA9 Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA9 Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA10 Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX11 Stanford University Medical Center, Stanford, CA, United States of Americahttp://journals.lww.com/10.1097/01.HS9.0000850364.78915.d9 |
| spellingShingle | J. C. Barrientos P. M. Barr A. R. Mato C. S. Tam P. Ghia C. Moreno N. E. Kay T. Siddiqi E. Szafer-Glusman C. Zhou L. Neumayr G. Krigsfeld W. G. Wierda T. Shanafelt PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) HemaSphere |
| title | PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) |
| title_full | PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) |
| title_fullStr | PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) |
| title_full_unstemmed | PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) |
| title_short | PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) |
| title_sort | pb1878 cross trial analysis of fixed duration ibrutinib i plus venetoclax v vs fludarabine f cyclophosphamide c and rituximab r as first line treatment for chronic lymphocytic leukemia cll |
| url | http://journals.lww.com/10.1097/01.HS9.0000850364.78915.d9 |
| work_keys_str_mv | AT jcbarrientos pb1878crosstrialanalysisoffixeddurationibrutinibiplusvenetoclaxvvsfludarabinefcyclophosphamidecandrituximabrasfirstlinetreatmentforchroniclymphocyticleukemiacll AT pmbarr pb1878crosstrialanalysisoffixeddurationibrutinibiplusvenetoclaxvvsfludarabinefcyclophosphamidecandrituximabrasfirstlinetreatmentforchroniclymphocyticleukemiacll AT armato pb1878crosstrialanalysisoffixeddurationibrutinibiplusvenetoclaxvvsfludarabinefcyclophosphamidecandrituximabrasfirstlinetreatmentforchroniclymphocyticleukemiacll AT cstam pb1878crosstrialanalysisoffixeddurationibrutinibiplusvenetoclaxvvsfludarabinefcyclophosphamidecandrituximabrasfirstlinetreatmentforchroniclymphocyticleukemiacll AT pghia pb1878crosstrialanalysisoffixeddurationibrutinibiplusvenetoclaxvvsfludarabinefcyclophosphamidecandrituximabrasfirstlinetreatmentforchroniclymphocyticleukemiacll AT cmoreno pb1878crosstrialanalysisoffixeddurationibrutinibiplusvenetoclaxvvsfludarabinefcyclophosphamidecandrituximabrasfirstlinetreatmentforchroniclymphocyticleukemiacll AT nekay pb1878crosstrialanalysisoffixeddurationibrutinibiplusvenetoclaxvvsfludarabinefcyclophosphamidecandrituximabrasfirstlinetreatmentforchroniclymphocyticleukemiacll AT tsiddiqi pb1878crosstrialanalysisoffixeddurationibrutinibiplusvenetoclaxvvsfludarabinefcyclophosphamidecandrituximabrasfirstlinetreatmentforchroniclymphocyticleukemiacll AT eszaferglusman pb1878crosstrialanalysisoffixeddurationibrutinibiplusvenetoclaxvvsfludarabinefcyclophosphamidecandrituximabrasfirstlinetreatmentforchroniclymphocyticleukemiacll AT czhou pb1878crosstrialanalysisoffixeddurationibrutinibiplusvenetoclaxvvsfludarabinefcyclophosphamidecandrituximabrasfirstlinetreatmentforchroniclymphocyticleukemiacll AT lneumayr pb1878crosstrialanalysisoffixeddurationibrutinibiplusvenetoclaxvvsfludarabinefcyclophosphamidecandrituximabrasfirstlinetreatmentforchroniclymphocyticleukemiacll AT gkrigsfeld pb1878crosstrialanalysisoffixeddurationibrutinibiplusvenetoclaxvvsfludarabinefcyclophosphamidecandrituximabrasfirstlinetreatmentforchroniclymphocyticleukemiacll AT wgwierda pb1878crosstrialanalysisoffixeddurationibrutinibiplusvenetoclaxvvsfludarabinefcyclophosphamidecandrituximabrasfirstlinetreatmentforchroniclymphocyticleukemiacll AT tshanafelt pb1878crosstrialanalysisoffixeddurationibrutinibiplusvenetoclaxvvsfludarabinefcyclophosphamidecandrituximabrasfirstlinetreatmentforchroniclymphocyticleukemiacll |